免疫检查点抑制剂在临床实践中的肾脏不良反应:ImmuNoTox研究
该研究回顾性分析了2015年1月至2017年7月在Hôpital Lyon Sud接受CPI治疗的连续患者,旨在描述CPI诱导的急性肾损伤(AKI)的流行病学、危险因素及临床特征。结果显示CPI诱导的AKI发生率为3.7%(13/352),且呈时间依赖性(暴露>3个月者为7.7%(11/143)),所有有组织学资料的病例均为急性肾小管间质性肾炎(ATIN),50%为1期AKI,无需肾脏替代治疗。
要点
- CPI诱导的AKI发生率为3.7%,暴露>3个月者升至7.7%。
- 所有有组织学资料的病例均为急性肾小管间质性肾炎(ATIN)。
- AKI严重程度多为轻度(1期占50%),无需肾脏替代治疗。
核心结论
- CPI诱导的AKI发生率为3.7%(13/352),且呈时间依赖性,暴露>3个月者为7.7%(11/143)。
- 所有有组织学资料的病例均为急性肾小管间质性肾炎(ATIN),尿沉渣改变不明显。
- AKI严重程度多为轻度(1期占50%),无需肾脏替代治疗。
研究设计与样本
- 回顾性分析2015年1月至2017年7月在Hôpital Lyon Sud接受CPI治疗的连续患者。
- 系统性回顾病历,每月收集血清肌酐水平、相关治疗及其他IRAEs发生情况。
- 排除由经典AKI病因(肾前性、梗阻性、脓毒性)解释的AKI发作。
主要发现
- CPI诱导的AKI发生率为3.7%(13/352),出现时间范围为1至16个月。
- 暴露>3个月的患者AKI发生率为7.7%(11/143)。
- CPI诱导的AKI患者更常发生其他IRAEs(77% vs 39%),但未与更高的AKI风险相关。
- 预先存在的慢性肾脏病(eGFR<60 ml/min)未与更高的CPI诱导AKI风险相关。
- CPI诱导AKI的治疗异质性大,包括停用CPI及不固定的全身皮质类固醇治疗。
关键数值与推荐
- CPI诱导的AKI发生率为3.7%(13/352)。
- 暴露>3个月的患者AKI发生率为7.7%(11/143)。
- 有组织学资料的病例均为急性肾小管间质性肾炎(ATIN)。
- AKI 1期占50%。
- CPI诱导AKI患者其他IRAEs发生率为77%,无AKI者为39%。
临床怎么用
- 接受CPI治疗期间应监测肾功能并早期识别AKI。
- CPI诱导AKI的最佳管理尚不明确,需肿瘤科与肾内科密切协作。
局限性
- 回顾性研究设计。
- CPI诱导AKI的治疗异质性大,最佳管理尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/OBJECTIVES: Acute Kidney Injury (AKI), induced by Checkpoint Inhibitors therapies (CPI-induced AKI), is an uncommon but severe Immune-Related Adverse Event (IRAE). The aim was to describe the epidemiology, risks factors, clinical, and laboratory characteristics of these renal adverse events (AEs) in a real-life cohort treatment. DESIGN/PARTICIPANTS: Consecutive patients undergoing a checkpoint inhibitor (CPI) therapy at the Hôpital Lyon Sud from January 2015 to July 2017 were included. A systematic retrospective analysis of medical files was performed, monthly serum creatinine levels, associated treatments, and occurrence of other IRAEs data were collected. AKI episodes explained by classic AKI aetiologies (prerenal, obstructive, septic) were excluded from the analysis. RESULTS: CPI-induced AKI incidence was 3.7% (13/352) and appeared to be time-dependent (7.7% (11/143) for patients with >3 months of CPI exposure), ranging from 1 to 16 months. All cases with available histology were acute tubulointerstitial nephritis (ATIN), with poor urinary sediment. The severity of AKI was mild (stage 1 in 50% of cases), with no need for renal-replacement therapy. Although CPI-induced AKI patients had more frequently other IRAEs (77% versus 39%), this was not associated with a greater risk of AKI. Pre-existing chronic kidney disease (defined as an estimated glomerular filtration rate (eGFR) <60 ml/min) was not associated with a greater risk of CPI-induced AKI. Treatments of CPI-induced AKI were heterogeneous, with discontinuation of CPIs, and inconstant systemic corticosteroid therapy. CONCLUSION: The monitoring of renal function and early identification of AKI during CPIs treatment is essential. The optimal management of CPI-induced AKI remains unclear and requires a close collaboration between the oncology and nephrology departments. CLINICAL RELEVANCY STATEMENT: Immune checkpoint inhibitors (CPIs) have dramatically improved patient outcomes in different malignant contexts such as melanoma, non-small cell lung cancers (NSCLC) and urologic cancers. Usually well-tolerated, CPIs are however associated with immune-related adverse events (IRAEs). Among them, acute kidney injury (AKI) is uncommon, and not well-described. Following the exponential increase in the prescription of CPIs, previously uncommon cases of IRAEs (such as AKI) have become common occurrence in referral centres. Data regarding the epidemiology, risk factors, or management of CPI-induced AKI are currently lacking or can be discordant. Data regarding CPI-induced AKI, in a large real-life cohort were reported herein.
引用
- Espi M, Teuma C, Novel-Catin E, et al. Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study. Eur J Cancer. 2021. PMID: 33607383. doi:10.1016/j.ejca.2021.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。